共 18 条
[1]
Kyle R.A., Bayrd E.D., The monoclonal gammopathies: Multiple myeloma and related cell disorders, (1976)
[2]
Wisloff F., Gulbrandsen N., Nord E., Therapeutic options in the treatment of multiple myeloma: Pharmacoeconomic and quality-of-life considerations, Pharmacoeconomics, 16, 4, pp. 329-341, (1999)
[3]
Wisloff F., Eika S., Hippe E., Et al., Measurement of health-related quality of life in multiple myeloma, Br J Haematol, 92, pp. 604-613, (1996)
[4]
Nord E., Wisloff F., Hjorth M., Et al., Cost-utility analysis of melphalan plus prednisone with or without interferon-α2b in newly diagnosed multiple myeloma, Pharmacoeconomics, 12, pp. 89-103, (1997)
[5]
Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6,633 patients from 27 randomized trials, J Clin Oncol, 16, pp. 3832-3842, (1998)
[6]
Gore M.E., Selby P.J., Viner C., Et al., Intensive treatment for multiple myeloma and criteria for complete remission, Lancet, 2, pp. 879-882, (1989)
[7]
Attal M., Harousseau J.-L., Stoppa A.M., Et al., A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma, N Engl J Med, 335, pp. 91-97, (1996)
[8]
Attal M., Harousseau J.-L., Stoppa A.M., Et al., High-dose therapy in multiple myeloma: An updated analysis of the IFM 90 protocol, Blood, 90, (1997)
[9]
Lenhoff S., Turesson I., Hjorth M., Et al., Intensive therapy in newly diagnosed multiple myeloma patients below 60 years: A prospective, controlled, population based study, Blood, 92, (1998)
[10]
Gulbrandsen N., Wisloff F., Health related quality of life of multiple myeloma patients treated with high dose chemotherapy and autologous peripheral blood stem cell transplantation, Blood, 92, (1998)